Search results
Results from the WOW.Com Content Network
Arsphenamine, also known as Salvarsan or compound 606, is an antibiotic drug that was introduced at the beginning of the 1910s as the first effective treatment for the deadly infectious diseases syphilis, relapsing fever, and African trypanosomiasis. [2] [3] This organoarsenic compound was the first modern antimicrobial agent. [4]
This was the first agent with a specific therapeutic effect to be created on the basis of theoretical considerations. Salvarsan proved to be amazingly effective, particularly when compared with the conventional therapy of mercury salts. Manufactured by Hoechst AG, Salvarsan became the most widely prescribed drug in the world.
At the Congress for Internal Medicine at Wiesbaden in April 1910, Ehrlich and Hata shared their successful clinical results, which showed that arsphenamine treated syphilis in humans. [7] The drug was marketed under the name Salvarsan and gained international acclaim as the "arsenic that saves" and as the first man-made antibiotic. [7]
1911 – Arsphenamine, also Salvarsan [1] 1912 – Neosalvarsan; 1935 – Prontosil (an oral precursor to sulfanilamide), the first sulfonamide; 1936 – Sulfanilamide; 1938 – Sulfapyridine (M&B 693) 1939 – sulfacetamide; 1940 – sulfamethizole; 1942 – benzylpenicillin, the first penicillin; 1942 – gramicidin S, the first peptide ...
The first effective treatment for syphilis was arsphenamine, discovered by Sahachiro Hata in 1909, during a survey of hundreds of newly synthesized organic arsenical compounds led by Paul Ehrlich. It was manufactured and marketed from 1910 under the trade name Salvarsan by Hoechst AG . [ 113 ]
Salvarsan was a synthetic drug produced to treat the STI syphilis. The drug was developed by Paul Ehrlich (1854-1915), a German medical scientist, and his team in 1909 after three years of research. Ehrlich coined the phrase ‘magic bullet’ to describe this new wonder drug.
Their discoveries were the result of the first organized team effort to optimize the biological activity of a lead compound through systematic chemical modifications. [1] This scheme is the basis for most modern pharmaceutical research. Both Salvarsan and Neosalvarsan are prodrugs – that is, they are metabolised into the active drug in the body.
The organoarsenic compound Salvarsan was the first synthetic chemotherapeutic agent, discovered by Paul Ehrlich. [21] The treatment, however, led to many problems causing long lasting health complications. [22] Around 1943 it was finally superseded by penicillin.